Video Series

An examination of data presented at ESMO 2023 from cohort 1 of the THOR-2 study of high-risk non–muscle invasive bladder cancer (HR NMIBC) with FGFR alterations.

Siamak Daneshmand, MD, explores unmet needs in the bladder cancer treatment landscape at ESMO 2023.

Financial considerations in MDS treatment are discussed.

Key opinion leaders discuss how patient quality of life is impacted by MDS treatment-associated challenges.

Toxicity management in HCC treatment is discussed by medical experts.

Dr Haumschild leads a discussion surrounding toxicity profiles specifically related to HCC.

Joseph M. Coney, MD, FACS, discusses the crucial role of ongoing community support and active engagement in boosting clinical trial recruitment and emphasizes the importance of establishing trust and increasing visibility to enhance patient confidence in the process.

A key opinion leader provides insight into key HFpEF treatment strategies.

Medical experts discuss strategies to connect with patients to alleviate concerns potentially associated with converting heart failure therapies.

Professionals speak to auto-substitution and its Impact on the shared decision-making process associated with biosimilars.

Medical experts discuss interchangeability designation requirements for biosimilars.

Stuart J Connolly, MD, FRCPC, discusses updated strategies for managing intracerebral hemorrhage, emphasizing the significance of timely diagnosis to improve hemostatic efficacy.

Richard Kim, MD, offers perspective regarding optimal use of health care resources in the management of HCC.

The decision to perform an EGD is evaluated between academic and community health care perspectives.

An expert perspective on the variety of MDS subtypes is provided.

Ryan Haumschild, PharmD, MS, MBA, CPEL, opens the discussion by defining the MDS disease state.

Concluding thoughts on data presented at ESMO 2023, and innovations still needed for improved survival of NSCLC—provided by Patrick Forde, MBBCh.

Patrick Forde, MBBCh, discusses advances in EGFR Exon 20 insertion-mutated NSCLC.

An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.

Joseph M. Coney, MD, FACS, discusses the importance of diverse representation in clinical trials for the ongoing advancement of safe and effective treatments, and underscores the need for cultivating trust within communities.

Experts offer concluding insights on unmet needs in NSCLC treatment and the future of patient care.

Specialists discuss unmet needs that continue to exist in treating patients with NSCLC despite advances in treatment, and how these impact patient outcomes.

Russell P. Gollard, MD, FACP, discusses ways to ensure access to appropriate treatment for rare diseases like hemophilia A, such as finding motivated providers with expertise and using utilization management strategies for cutting-edge care to bridge the gap between available community treatments and emerging therapies, ultimately benefiting patients.

Heart failure treatment strategies are emphasized based off recent clinical trial data.

Utilization of the four pillars in heart failure therapy are highlighted as aggressive first-line treatment strategies.

Insight surrounding the switch from reference drugs to biosimilars is provided by Bincy Abraham, MD, MS.

Vibeke Strand, MD, evaluates implementation of biosimilars in patients with no history of reference biologic use.

Cost-effectiveness considerations are highlighted by Dr Abou-Alfa.

Treatment continuity and adherence in HCC can be encouraged through patient education and engagement.

Patrick Forde, MBBCh, discusses ALK rearrangement in NSCLC and highlights ALINA trial results from ESMO 2023.